Is Collegium Pharmaceutical Inc (COLL) overvalued?
Collegium Pharmaceutical Inc (COLL) is a drug manufacturers - specialty & generic company listed on NASDAQ.
This page asks whether Collegium Pharmaceutical Inc (COLL) looks expensive on cached numbers — not a short thesis.
Latest reported COLL revenue for 2024-12-31 was $181.9M. Net income was $69.2M. Revenue was up 14.2% from 2024-09-30 to 2024-12-31. COLL currently screens at market cap $1.12B and trailing P/E 16.8.
COLL currently screens at market cap $1.12B and trailing P/E 16.8. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next COLL 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the COLL stock page for the full model, not this heading.
Not investment advice.